ER plays a substantial role in the growth of breast cancer by regulation of cell cycle proteins, such as cyclinD1, E2F1, and c-myc, among others [37, 59–61], and tumor cells resistant to CDK4/6i continue to rely on the ER pathway to drive tumor growth. Here, E2F1 is linked to neoplasm.